Figure 6
From: Immunoprognostic model of lung adenocarcinoma and screening of sensitive drugs
CMap database drug screening and cytological activity validation. (a) Optimal compounds and their structures screened from the CMap database. (b) DMSO solvent toxicity assay. (c) Inhibition rate of the resveratrol compound on A549 cells. (d) Inhibition rate of the methotrexate compound on A549 cells. (e) Inhibition rate of the phenoxybenzamine compound on A549 cells.
